Incidence of depression and antidepressant prescription in patients with COPD: A large UK population-based cohort study - 20/04/22
Abstract |
Background |
Depression is frequently reported in patients with Chronic Obstructive Pulmonary Disease (COPD). However, there is little information available on the incidence of depression following a COPD diagnosis.
Objective |
To determine the incidence of a new diagnosis of depression or antidepressant prescription in people with and without a COPD diagnosis.
Methods |
A matched cohort study was conducted using The Health Improvement Network database. Patients with confirmed COPD diagnosis were matched to up to four subjects without a COPD diagnosis by age, sex and GP practice. Cox proportional hazards models were used to assess the incidence rates of depression and antidepressant prescription.
Results |
44,362 patients with COPD and 124,140 subjects without COPD were included. The incidence rate of depression per 1000 person-years following COPD diagnosis was greater (11.4; 95% CI: 10.9–11.8) compared to subjects without COPD (5.7; 95% CI: 5.5–5.8) (p < 0.001). Patients with COPD were 42% more likely to have an incident depression (adjusted hazard ratio [aHR]: 1.42; 95% CI: 1.32–1.53; p < 0.001), and 40% more likely to be prescribed an antidepressant (aHR: 1.40; 95% CI: 1.35–1.45; p < 0.001). The incidence to either depression or antidepressant prescription was also greater for patients with COPD (aHR: 1.41; 95% CI: 1.36–1.46; p < 0.001). Patients with COPD and worse breathlessness had a higher risk of incident depression compared to patients with less breathlessness.
Conclusion |
Healthcare providers managing patients with COPD should be alert to the existence of depression and aware of its symptoms and consequences.
Le texte complet de cet article est disponible en PDF.Highlights |
∙ | Depression is among the common comorbidities in patients with COPD, yet has not been well studied. |
• | ∙The incidence of depression and antidepressant prescriptions are greater in patients with COPD than those without. |
• | ∙Healthcare professionals should be vigilant to symptoms and target accordingly. |
Keywords : COPD, Depression, Mental health, Antidepressant
Plan
Vol 196
Article 106804- mai 2022 Retour au numéro
Article précédent
- The six-minute walk test in sarcoidosis associated pulmonary hypertension: Results from an international registry
- Rohit Gupta, Robert P. Baughman, Steven D. Nathan, Athol U. Wells, Vasilis Kouranos, Esam H. Alhamad, Daniel A. Culver, Joseph Barney, Eva M. Carmona, Francis C. Cordova, Marloes Huitema, Mary Beth Scholand, Marlies Wijsenbeek, Sivagini Ganesh, Surinder S. Birring, Laura C. Price, Stephen John Wort, Oksana A. Shlobin
- The association of baseline sarcoidosis measurements with 6-month outcomes that are of interest to patients: Results from the On-line Sarcoidosis Assessment Platform Study (OSAP)
- Marc A. Judson, Recai Yucel, Sara Preston, Edward S. Chen, Daniel A. Culver, Nabeel Hamzeh, Elyse E. Lower, Nadera J. Sweiss, Dominique Valeyre, Marcel Veltkamp, David E. Victorson, Jennifer L. Beaumont, Noopur Singh, Tricha Shivas, Rachel Vancavage, Robert P. Baughman
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?